Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beijing Biotech
Actuate Therapeutics Inc.
Bristol-Myers Squibb
RasCal Therapeutics, Inc.
Filamon LTD
AstraZeneca
Hoffmann-La Roche
UMC Utrecht
Essen Biotech
St. Jude Children's Research Hospital
xCures
Swansea Bay University Health Board
University of Nebraska
Adela, Inc
Var2 Pharmaceuticals
Novartis
Mayo Clinic
Mayo Clinic
Degron Therapeutics Co.
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Day One Biopharmaceuticals, Inc.
AVM Biotechnology Inc
LigaChem Biosciences, Inc.
Ikena Oncology
Washington University School of Medicine
Day One Biopharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Second Life Therapeutics
Azienda Ospedaliera di Padova
Apollomics Inc.
Columbia University
Tempus AI
Stanford University
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
BerGenBio ASA
Universidade Federal de Pernambuco
Taproot Health
ABM Therapeutics Corporation
Wake Forest University Health Sciences
Mayo Clinic
University of Sydney
Cedars-Sinai Medical Center
Sumitomo Pharma America, Inc.
Hoffmann-La Roche